Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization

Table 2

Changes in best-corrected visual acuity (ETDRS), central macular thickness, and intraocular pressure during the 12-month monitoring period.

Time; (months)	Change in ETDRS best-corrected visual acuity (letters)			Change in central macular thickness (𝜇m)			IOP (mmHg)
	Early	Mid	𝑃	Early	Mid	𝑃	Early	Mid	𝑃
1	21.8±8.4	14.9±9.7	0.015	185.3±37.7	132.2±32.3	0.0001	13.6±4.8	13.4±4.2	0.885
3	29.3±9.9	18.4±11.5	0.0016	182.4±39.4	153.7±31.2	0.011	13.5±3.4	14.2±2.5	0.449
6	35.2±11.8	21.1±13.1	0.005	196.4±43.9	157.7±49.7	0.0089	14.6±2.6	13.9±2.8	0.395
9	37.6±15.3	25.8±18.1	0.029	185.7±46.8	117.3±54.1	0.0001	13.4±2.5	14.3±3.2	0.301
12	36.9±12.2	24.3±16.2	0.005	195.3±58.3	128.8±43.3	0.0001	14.4±3.1	15.3±3.5	0.371

Data are presented as the mean ± standard error.
Changes in BCVA and CMT are compared to preinjection values.
IOP: intraocular pressure.